Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering by Strobel, Hannah A. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2018-11-21 
Targeted Delivery of Bioactive Molecules for Vascular Intervention 
and Tissue Engineering 
Hannah A. Strobel 
Worcester Polytechnic Institute 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cardiovascular Diseases Commons, Medical Pharmacology Commons, Medicinal and 
Pharmaceutical Chemistry Commons, Medicinal Chemistry and Pharmaceutics Commons, Molecular, 
Cellular, and Tissue Engineering Commons, Nanomedicine Commons, Pharmacology Commons, Surgical 
Procedures, Operative Commons, and the Therapeutics Commons 
Repository Citation 
Strobel HA, Qendro EI, Alsberg E, Rolle MW. (2018). Targeted Delivery of Bioactive Molecules for Vascular 
Intervention and Tissue Engineering. Open Access Articles. https://doi.org/10.3389/fphar.2018.01329. 
Retrieved from https://escholarship.umassmed.edu/oapubs/3667 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
fphar-09-01329 November 21, 2018 Time: 14:46 # 1
REVIEW
published: 21 November 2018
doi: 10.3389/fphar.2018.01329
Edited by:
Chris A. Bashur,
Florida Institute of Technology,
United States
Reviewed by:
Blanka Sharma,
University of Florida, United States
Hui Li,
University of California,
San Francisco, United States
*Correspondence:
Marsha W. Rolle
mrolle@wpi.edu
†Present address:
Eben Alsberg,
Departments of Bioengineering and
Orthopaedics, The University
of Illinois, Chicago, IL, United States
Specialty section:
This article was submitted to
Integrative and Regenerative
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 15 March 2018
Accepted: 29 October 2018
Published: 21 November 2018
Citation:
Strobel HA, Qendro EI, Alsberg E
and Rolle MW (2018) Targeted
Delivery of Bioactive Molecules
for Vascular Intervention and Tissue
Engineering.
Front. Pharmacol. 9:1329.
doi: 10.3389/fphar.2018.01329
Targeted Delivery of Bioactive
Molecules for Vascular Intervention
and Tissue Engineering
Hannah A. Strobel1, Elisabet I. Qendro2, Eben Alsberg3† and Marsha W. Rolle1*
1 Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA, United States, 2 Graduate School
of Biomedical Sciences, University of Massachusetts Medical School, Worcester, MA, United States, 3 Department of
Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States
Cardiovascular diseases are the leading cause of death in the United States.
Treatment often requires surgical interventions to re-open occluded vessels, bypass
severe occlusions, or stabilize aneurysms. Despite the short-term success of such
interventions, many ultimately fail due to thrombosis or restenosis (following stent
placement), or incomplete healing (such as after aneurysm coil placement). Bioactive
molecules capable of modulating host tissue responses and preventing these
complications have been identified, but systemic delivery is often harmful or ineffective.
This review discusses the use of localized bioactive molecule delivery methods to
enhance the long-term success of vascular interventions, such as drug-eluting stents
and aneurysm coils, as well as nanoparticles for targeted molecule delivery. Vascular
grafts in particular have poor patency in small diameter, high flow applications,
such as coronary artery bypass grafting (CABG). Grafts fabricated from a variety of
approaches may benefit from bioactive molecule incorporation to improve patency.
Tissue engineering is an especially promising approach for vascular graft fabrication
that may be conducive to incorporation of drugs or growth factors. Overall, localized
and targeted delivery of bioactive molecules has shown promise for improving the
outcomes of vascular interventions, with technologies such as drug-eluting stents
showing excellent clinical success. However, many targeted vascular drug delivery
systems have yet to reach the clinic. There is still a need to better optimize bioactive
molecule release kinetics and identify synergistic biomolecule combinations before the
clinical impact of these technologies can be realized.
Keywords: drug delivery, vascular tissue engineering, vascular graft, vascular repair, drug eluting stent,
nanoparticle, aneurysm
INTRODUCTION
Every 40 seconds an American dies from cardiovascular disease, the leading cause of death in
the United States. It is estimated that by 2030, 43.9% of Americans will be living with some
form of cardiovascular disease (Go et al., 2014). Some diseases, such as atherosclerosis, can lead
to life-threatening blood vessel occlusions. While some preventative medications exist, invasive
procedures such as angioplasty, stenting, and bypass surgery are often required to restore blood
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vessel patency. However, these procedures provide only
temporary solutions; it is estimated that up to 15–50% of
angioplasties, 16–30% of saphenous vein bypass grafts, and up
to 90% of synthetic coronary bypass grafts fail within 1–3 years
(Lemson et al., 2000; Goldman et al., 2011; Kennealey et al., 2011;
Siracuse et al., 2012; Marmagkiolis et al., 2014). Other vascular
diseases such as aneurysm cannot currently be prevented or
treated with medication, and must be surgically repaired.
Improvements in peripheral or coronary artery bypass
grafting (CABG) in particular have made little clinical progress
over the past several decades. The standard of care is to use
autologous saphenous veins or internal mammary arteries as
donor graft material. However, autologous vein and artery grafts
are unavailable in approximately one-third of patients due to
severity of vascular disease or previous surgeries (Veith et al.,
1979). Synthetic grafts can be effective for surgical bypass of
large diameter arteries. Coatings with molecules such as heparin
have significantly improved outcomes in applications such as
femoropopliteal bypass grafts (Devine et al., 2004; Walluscheck
et al., 2005; Lindholt et al., 2011). However, synthetic materials
still fail consistently when used as bypass grafts for high-
flow, small diameter vessels, such as peripheral and coronary
arteries (Pashneh-Tala et al., 2015). When used for CABG,
polytetrafluoroethylene (PTFE) has a 2-year patency rate of only
32%, compared to greater than 90% for saphenous vein grafts
(Chard et al., 1987; Shah et al., 2005; Hadinata et al., 2009). Thus,
new alternatives may be needed for patients who lack suitable
autologous grafts for bypass procedures.
Tissue engineered blood vessels (TEBVs) are being
investigated as alternatives to synthetic grafts for CABG and
other bypass grafting applications. TEBVs may be advantageous
because they may more closely mimic the native structure and
function of arteries than synthetic materials. In some cases,
TEBVs may degrade and be entirely replaced by native tissue
(Hibino et al., 2010). Several TEBVs have already been tested
in clinical trials for hemodialysis access (Wystrychowski et al.,
2014; Lawson et al., 2016) and cavopulmonary conduits (Hibino
et al., 2010). While many advances have been made, TEBVs
still face challenges such as incomplete endothelialization,
thrombosis, stenosis following implantation, and limited
function. For example, a recent clinical trial for hemodialysis
access grafts reported 1-year primary patency rates of 28%,
although secondary patency rates were 89% (Lawson et al., 2016).
The low primary patency was primarily due to thrombosis. While
this is an improvement over synthetic PTFE grafts, which have
41% primary and 59% secondary 1-year patency rates (Hodges
et al., 1997), there is still room for improvement. Additionally,
no TEBVs have moved forward into clinical trials specifically for
CABG, as this is especially challenging due to the small diameter
and high flow rate in the coronary artery. Controlled release of
growth factors and other molecules directly within TEBVs may
help address some of these problems.
While many different drugs have shown clinical efficacy for
treating vascular disease, many are either ineffective or toxic
when delivered systemically (Bea et al., 2002; Johnson et al.,
2005; Marupudi et al., 2007). For example, statins, which are
typically used to prevent restenosis, have also been shown to
reverse existing atherosclerotic lesions, but only at doses that are
toxic to humans (Bea et al., 2002; Johnson et al., 2005). Targeted
delivery of these drugs using biomaterial and tissue engineering
approaches may help solve this problem by allowing a much
higher dose to be delivered directly to the diseased site.
In this review, we discuss how controlled release of drugs
and growth factors can be used for a wide range of vascular
intervention applications, from targeted treatment of vascular
diseases to improving the function of TEBVs for bypass
grafting. Many approaches have been developed to achieve
targeted bioactive molecule delivery and localized release in the
vasculature, including implantation of drug-eluting stents or
bypass grafts, or delivery of specialized bioactive molecule-loaded
nanoparticles designed to target sites of injury or disease.
VASCULAR DISEASE AND
INTERVENTION – OPPORTUNITIES FOR
TARGETED DRUG DELIVERY
Localized drug delivery is an ideal strategy for treating vascular
diseases such as atherosclerosis, restenosis, and aneurysm, as
these focal diseases affect only a small region of the blood
vessel. Systemic treatments for these diseases are often ineffective,
or cause harmful side effects. To address this challenge,
biomaterial approaches are being developed and tested clinically
for delivering therapeutics directly to sites of injury and disease.
Atherosclerosis and Restenosis
Atherosclerosis is characterized by the buildup of lipids in
the vascular wall, triggered by endothelial dysfunction and
inflammation. If left untreated, unstable lesions with necrotic
cores may rupture and trigger a life-threatening thrombosis. Even
if they do not rupture, lesions can begin to occlude the vessel
and restrict blood flow to vital organs. While some preventative
medications exist, treatments for large or ruptured lesions are
largely invasive. A balloon angioplasty can be inflated in a partial
occlusion to restore blood flow (Figure 1A; balloon shown in
blue). Stents can also be put in place to mechanically hold the
vessel open for a longer period (Figure 1A). In severe cases, the
diseased area may need to be replaced or bypassed altogether
with a vascular graft (Libby and Theroux, 2005) (Figure 1B).
While effective, each of these invasive treatments can damage the
endothelium, triggering a cascade of events that leads to intimal
hyperplasia (restenosis), or the overgrowth of smooth muscle
cells (SMCs) into the vessel lumen (Kornowski et al., 1998).
Drug-eluting biomaterials may be one solution to overcoming
these problems by locally delivering treatments to heal or prevent
these diseases.
Aneurysm
Aneurysms are caused by the localized degradation of the arterial
elastin and elastic fibers by matrix metalloproteinases (MMPs).
This causes the vascular wall to dilate and weaken, and ultimately
rupture (Thompson and Parks, 1996). There are two types of
aneurysms. Fusiform aneurysms affect the entire circumference
Frontiers in Pharmacology | www.frontiersin.org 2 November 2018 | Volume 9 | Article 1329
fphar-09-01329 November 21, 2018 Time: 14:46 # 3
Strobel et al. Targeted Drug Delivery for Vascular Interventions
FIGURE 1 | Current interventions for vascular diseases, and their modes of failure. Stenosis (A), caused by atherosclerosis or intimal hyperplasia, is frequently
treated with stent placement [blue balloon in (A) used to deploy stent] to restore patency. However, in-stent restenosis is a frequent complication. In severe cases of
occlusion (B), a complete vessel bypass may be necessary. With bypass grafting, there is a risk of failure due to thrombosis or restenosis at graft anastomoses.
Aneurysms (C) can be treated with an aneurysm coil, to fill the aneurysmal sac and prevent further dilation. However, over time coils can begin to leak, allowing fluid
to re-enter and further enlarge the aneurysm.
of the vessel region, whereas saccular aneurysms affect only a
focal region of the circumference.
There are limited options for treating aneurysms. Once they
reach a critical size, surgical intervention becomes necessary.
For fusiform aneurysms, the affected region is either replaced or
reinforced with a synthetic vascular graft (Tarafdar and Gannon,
2017). For smaller saccular aneurysms in regions such as the
brain, the dilated region can be surgically “clipped,” or tied
off, so blood cannot flow into the dilated region, although this
procedure is highly invasive. In some cases, “flow diverters”
are used, which are specially designed stents that block blood
from entering the aneurysm. Alternatively, a metallic coil can
be guided up through the vasculature to the aneurysm, and
essentially “stuffed” in to fill the dilation and prevent blood from
entering (Pierot and Wakhloo, 2013) (Figure 1C).
Drug Delivery Opportunities for Vascular
Intervention
There are numerous methods for incorporating drugs or growth
factors into biomaterials, summarized schematically in Figure 2.
Molecules such as heparin can be immobilized on the material
surface, an approach which is frequently utilized for reducing
thrombosis risk on synthetic vascular grafts (Biran and Pond,
2017). Growth factors can also be bound to heparin-coated
surfaces. This strategy results in a longer, sustained release of
growth factors than binding them to non-heparinized surfaces
(Jeon et al., 2007).
Alternatively, therapeutics can be encapsulated within
biomaterials during fabrication. For example, with emulsion
electrospinning, growth factors are combined with a polymer
solution and then electrospun into a scaffold with growth
factor-encapsulating fibers (Zhang et al., 2013). Depending
on the biomaterial used, molecules encapsulated by materials
may be released by affinity interactions, diffusion, bulk or
surface degradation of the material; or a combination of release
mechanisms. This is advantageous because it enables sustained
tunable release of the molecule with minimal burst release (Lee
et al., 2007). Burst releases occur when a large portion of the
molecules are released in a very short period of time, which can
have toxic or other off-target effects on cells depending on the
molecule released.
Molecules can also be loaded via diffusion into materials
after fabrication, by soaking the material in a bioactive factor
solution. For example, growth factors can diffuse into gelatin
scaffolds and bind electrostatically to the gelatin. The growth
factor is then released by dissociation and diffusion as the gelatin
proteolytically degrades (Tabata and Ikada, 1998). Growth factor
loading and release methods are reviewed in greater detail in Lee
et al. (2011).
Each of these loading techniques results in materials
with different bioactive factor release kinetics. Different types
of release kinetics may be ideal for different applications.
This wide range of available systems and achievable release
kinetics may enable drug-delivery systems to be customized
for many applications in tissue engineering and regenerative
medicine.
Device Design Criteria
When designing drug-eluting biomaterials for tissue engineering
or regenerative medicine, many factors need to be considered.
Frontiers in Pharmacology | www.frontiersin.org 3 November 2018 | Volume 9 | Article 1329
fphar-09-01329 November 21, 2018 Time: 14:46 # 4
Strobel et al. Targeted Drug Delivery for Vascular Interventions
FIGURE 2 | Methods for incorporating bioactive molecules into medical devices or tissue engineered grafts. Growth factors can be tethered to graft surfaces,
incorporated directly into material coatings, incorporated directly within scaffold materials during fabrication, or absorbed into the material post-fabrication.
It is critical that the material used is biocompatible and will
not trigger any local or systemic toxic effects. Many drugs
are released as material degrades, and polymer degradation
products can be harmful to cells (Higgins et al., 2003).
Consistency in the manufacturing process is also important;
uneven drug loading may cause too much or too little drug
to be delivered. The material fabrication process also plays a
role in the effectiveness of a therapeutic. Growth factors, nucleic
acids, and many drugs may denature and/or degrade upon
heating, so if a heating step is required in the manufacturing
process, the bioactivity of the molecules may be diminished.
Any material intended for cell culture or implantation must
be sterilized without degrading, and may need to be stored
for extended periods of time. In some cases, it may be
possible to load the material with a drug directly before use.
However, this is not always an option, especially for treatments
such as stent placement or angioplasty, where time is often
a critical factor. Thus, an ideal drug-loaded biomaterial is
stable enough for long-term storage and can be available
off-the-shelf.
More specific design criteria varies considerably depending
on the disease, target mechanism, delivery mechanism, and
molecule being delivered. Thus, it is challenging to create
broad specifications for drug-eluting biomaterial systems. The
delivery mechanism must be designed in such a way that
the molecule can reach its intended target. For example, a
therapeutic that inhibits SMC proliferation, such as paclitaxel,
must be able to penetrate the endothelium to reach the
medial layer of the blood vessel. However, a nanoparticle
that targets the endothelium, such as vascular endothelial
growth factor (VEGF), may not need to penetrate beyond
the luminal surface of the blood vessel. Different molecules
may require different doses or release kinetics to be effective,
depending on how long they remain in the tissue. For
example, paclitaxel accumulates and remains in tissue for longer
periods of time than sirolimus, and thus does not require as
prolonged of a release (discussed further below) (Levin et al.,
2004).
LOCALIZED DRUG DELIVERY FROM
VASCULAR STENTS
Stent placement has been used to restore blood flow following
partial vessel occlusions since the 1980s. However, the original
bare-metal stents can trigger life threatening conditions such as
thrombosis, and have high rates of restenosis (Chen et al., 2006).
Drug-eluting stents can provide localized delivery of therapeutics
directly to the blood vessel wall and prevent in-stent restenosis.
When designing drug-eluting stents, many factors need to
be considered. Optimizing the release kinetics is critical for
maximizing drug effectiveness and minimizing adverse effects.
Release profile and drug distribution within the tissue can be
affected by a number of factors, including the properties of the
drug (Bozsak et al., 2015), stent or coating material and drug
release mechanism (Acharya and Park, 2006), stent geometry (Seo
et al., 2016), coating thickness, stent-induced changes in blood
flow patterns (Seo et al., 2016), initial drug loading concentration
(Bozsak et al., 2015), presence of thrombi in and around the
stent (Hwang et al., 2005), and drug absorption capacity of
the surrounding tissue (Balakrishnan et al., 2007). Therapeutics
discussed in this section are summarized in Table 1.
Paclitaxel and Sirolimus-Eluting Stents
The two original drug-eluting stents, Cypher and Taxus,
were fabricated from stainless-steel scaffolds with a permanent
polymer coating designed to release sirolimus (Cypher) or
paclitaxel (Taxus). Both of these drugs are known to prevent
SMC proliferation and migration (Marx et al., 1995; Axel et al.,
1997). The Cypher and Taxus stents were approved by the
FDA based on their ability to reduce restenosis compared
to bare metal stents (Sousa et al., 2001; Grube et al., 2002;
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TABLE 1 | Molecules delivered for atherosclerosis treatment.
Molecule Delivery mechanism Effects
Sirolimus Drug eluting stents Inhibit cellular proliferation and migration
Paclitaxel Drug eluting stents, Nanoparticles Inhibit cellular proliferation and migration
Novolimus Bioresorbable vascular scaffolds Inhibit cellular proliferation and migration
Everolimus Bioresorbable vascular scaffolds Inhibit cellular proliferation and migration
Amphilimus Nanoparticles in drug eluting stents Inhibit cellular proliferation and migration
Biolimus Drug eluting stents Inhibit cellular proliferation and migration
Heparin Drug eluting stents, Synthetic vascular grafts Prevent thrombosis
CD34 TEBVs, Drug eluting stents Accelerate endothelialization
VEGF Drug eluting stents Accelerate endothelialization
Simvastatin Nanoparticles Inhibit SMC proliferation and migration, promote
endothelial health, anti-inflammatory, lower cholesterol
IL-10 Nanoparticles Anti-inflammatory
Prednisolone Nanoparticles Anti-inflammatory
Ac2-26 Nanoparticles Anti-inflammatory
Carmustine Nanoparticles Inhibit cellular proliferation
VEGF plasmids Nanoparticles Increase VEGF production to heal damaged
endothelium
SiRNA, microRNA Drug eluting stents, nanoparticles Enhance endothelial function, prevent macrophage
accumulation, reduce adhesion molecule receptors,
suppress SMC proliferation
Summary of bioactive factors discussed in Sections “Localized Drug Delivery From Vascular Stents” and “Nanoparticle-Mediated Drug Delivery for Restenosis Prevention,”
their delivery mechanisms, and effects.
Morice et al., 2002; Colombo et al., 2003; Moses et al., 2003; Stone
et al., 2004). However, reduced endothelialization and delayed
healing compared to bare-metal stents led to high incidences of
late in-stent thrombosis. This may be attributed to drug-mediated
inhibition of endothelial cell (EC) proliferation, in addition to
drug effects on target SMCs, and localized inflammation (Farb
et al., 2001; Joner et al., 2006; Pfisterer et al., 2006; Finn et al.,
2007a,b; Nakazawa et al., 2008). Sensitivities to the materials used
may also play a role in prolonged inflammation (Suzuki et al.,
2001).
Paclitaxel and sirolimus have different transport dynamics
through the arterial wall, leading paclitaxel to accumulate in
the adventitia, rather than the media (Levin et al., 2004).
Additionally, modeling simulations indicate that paclitaxel
unbinds from tissue 20 times slower than sirolimus, thus causing
it to remain in the arterial wall for a longer duration than
sirolimus (Balakrishnan et al., 2007; Bozsak et al., 2014; Bozsak
et al., 2015). Because the Taxus stent delivers a relatively high dose
of paclitaxel over 30 days, it may accumulate in very high levels
in the arterial wall and trigger localized inflammation (Radeleff
et al., 2010; Bozsak et al., 2015). This may be one possible
explanation for why paclitaxel-eluting stents are less effective
than sirolimus-eluting stents (Dibra et al., 2005; Kastrati et al.,
2005). It is possible that decreasing the loading concentration of
paclitaxel in stents and releasing either one short burst, or a much
slower release over a period of years, may reduce buildup in the
arterial wall, and prevent SMC hyperplasia without delaying the
healing process (Bozsak et al., 2014; Bozsak et al., 2015).
The idea of designing stents with a large initial burst release
has been applied to paclitaxel-eluting angioplasty balloons. These
balloons deliver a short burst of targeted therapy to a diseased
region, which accumulates and remains in the arterial wall for
an extended period. Paclitaxel-eluting balloons have reduced
restenosis rates compared to traditional angioplasty balloons
(Rittger et al., 2012; Byrne et al., 2013; Miura et al., 2017).
While paclitaxel-eluting stents have largely been phased out, it
is possible that further optimization of their release kinetics may
have improved clinical results. This highlights the importance
of understanding and tuning the release kinetics and diffusion
properties of therapeutics released by stents and other systems
for each specific drug and clinical indication.
Second Generation Drug-Eluting Stents
Second-generation drug-eluting stents used similar designs to
Taxus and Cypher, but with improved drug release kinetics, more
biocompatible materials, and altered stent geometry. There are
numerous commercially available variations of these designs,
most of which elute sirolimus derivatives. As a result of these
changes, clinical outcomes have improved compared to first
generation designs, especially in improving stent safety, and this
has led second generation drug-eluting stents to become the
current gold standard (Navarese et al., 2013; Valgimigli et al.,
2014; Kobayashi et al., 2016). However, others have suggested
that the improvements have not reduced the overall risk of late
in-stent thrombosis, indicating that a different approach to stent
design is needed (Tada et al., 2013). Second generation drug-
eluting stents are reviewed in detail in Ho et al. (2016) and
Akinapelli et al. (2017).
Other Stent Designs
Despite the success of second-generation drug-eluting stents,
restenosis and thrombosis remain a problem, and currently
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available drug-eluting stents may not be appropriate for all
patients. Thus, other approaches to stent design are being
developed. Immobilized heparin on the stent surface may
be an additional option for preventing thrombosis. There is
currently one commercially available heparin-eluting stent, the
Viabahn stent, which is fabricated from a nitinol base with a
heparin-bound ePTFE coating. The Viabahn stent demonstrated
improved patency rates in clinical trials compared to bare-metal
stents (Lammer et al., 2013; Saxon et al., 2013).
Polymer-free drug-eluting stents may be advantageous for
patients with polymer sensitivities. While loading drugs onto
metallic surface can be challenging, several different strategies
have proven effective. For example, the Cre8 stent releases
nanoparticles containing amphilimus from reservoirs on the
abluminal side of the stent (Carrie et al., 2012). The BioFreedom
stent adheres biolimus A9 to a micro-structured metallic surface
(Urban et al., 2015). The VESTAsync stent has sirolimus loaded
into a microporous hydroxyapatite coating (Costa et al., 2009; van
der Giessen et al., 2009). These techniques have had comparable
clinical results to second-generation drug-eluting stents, and may
reduce the risk of delayed healing (Costa et al., 2009; Carrie et al.,
2012; Urban et al., 2015).
More complex stent designs have focused on further
optimizing drug release kinetics, in addition to material and
mechanical properties. Stents containing reservoirs can be filled
with drugs that are released through small holes on the abluminal
side of the stent only, allowing for more targeted drug delivery
over a longer period (Finkelstein et al., 2003; Krucoff et al., 2008).
Other groups have tried using a layer-by-layer assembly approach
to coating stents, with materials such as chitosan or hyaluronic
acid and therapeutics such as heparin and growth factors, to
further control and customize drug release kinetics (Meng et al.,
2009; Hossfeld et al., 2013; Liu et al., 2013; Su et al., 2013).
Layer-by layer assembly can allow for the release of multiple
drugs, which may be more effective than single-drug approaches.
For example, coatings releasing sirolimus and heparin have
been tested, which act to prevent restenosis and thrombosis,
respectively (Su et al., 2013). Heparin also has a high affinity for
growth factors, which become immobilized on its surface. In Liu
et al. (2013), heparin was immobilized to the stent surface using
an avidin–biotin system, and then CD34 and VEGF are bound
to the heparin, with the goal of accelerating endothelialization
(Liu et al., 2013). Both of these studies have shown promise
in vitro.
Bioresorbable Vascular Scaffolds
More recent studies are focused on creating bioresorbable
drug-eluting stents, or vascular scaffolds, from either
metallic or polymeric materials. By completely degrading,
these bioresorbable vascular scaffolds may alleviate many of
the negative effects observed with metallic polymer-coated
drug-eluting stents. They may also allow for the restoration of
normal function and vasomotion of the vessel (Serruys et al.,
2016). With non-degradable stents, a permanent focal decrease in
vascular compliance can cause regions of compliance mismatch,
increasing the risk of restenosis (Farhan et al., 2009; Selvarasu
et al., 2011).
The two most widely used polymeric bioresorbable vascular
scaffolds, the DESolve and Absorb bioresorbable vascular
scaffolds, are both fabricated from poly-L-lactic acid (PLLA),
and elute novolimus and everolimus, respectively. The DESolve
bioresorbable vascular scaffold degrades completely in about
1 year, while the Absorb bioresorbable vascular scaffold
degrades in approximately 3 years. Initial clinical trials of both
bioresorbable vascular scaffolds were promising (Abizaid et al.,
2016; Serruys et al., 2016). However, recent studies suggested
the overall risk of death is similar between second generation
drug-eluting stents and bioresorbable vascular scaffolds (Pandya
et al., 2016; Stone et al., 2016; El-Hayek et al., 2017), and the risk
of very late thrombosis (1–2 years after implantation) may even
be higher than in drug-eluting stents (Toyota et al., 2017). Still,
more time is needed to determine the extent of other potential
long-term benefits, such as restored vessel function.
In addition to degradable polymers, degradable metals
can also be used for bioresorbable vascular scaffolds. The
DREAMS 2G bioresorbable vascular scaffolds is fabricated from
a magnesium alloy with a sirolimus-loaded PLA coating. When
the magnesium alloy degrades, it is first converted into hydrated
magnesium oxide, and then into magnesium phosphate. Then
it is replaced by amorphous calcium phosphate, which remains
in the tissue. The magnesium diffuses out of the tissue and is
absorbed by the body. The entire degradation process takes about
1 year (Haude et al., 2016). In clinical trials, the DREAMS 2G
bioresorbable vascular scaffold performed similarly to polymeric
bioresorbable vascular scaffolds, although long-term studies
and direct comparisons are still needed (Haude et al., 2016).
Bioresorbable vascular scaffolds are reviewed in detail in Bowen
et al. (2016) and Ho et al. (2016).
Future of Stent Design
While release kinetics are critical to the performance of
drug-eluting stents, they are extremely challenging to measure
in vivo. This makes it difficult to engineer stents with specific
release profiles, and several design iterations may be needed
to achieve the desired outcome. Recent mathematical models
combining in vitro with in vivo studies have increased our
understanding of therapeutic drug release from stents, which may
help reduce the number of iterations needed for success (McGinty
et al., 2013, 2017; Bozsak et al., 2014, 2015). In the future, these
models may be key to fabricating stents that deliver therapeutics
at doses that inhibit SMC proliferation and prevent restenosis,
but without toxic effects on ECs that have resulted in delayed
healing, inhibition of re-endothelialization, and late thrombosis.
Many new molecules also hold promise for improving
future drug-eluting stent designs. The possibility of delivering
small-interfering ribonucleic acid (siRNA delivery) is currently
being investigated (Hossfeld et al., 2013; Che et al., 2016; Cho and
Park, 2017). siRNA are short double-stranded RNA molecules
that interfere with the expression of specific genes. Stents have
incorporated siRNA with the goal of reducing adhesion molecule
receptors to reduce thrombosis and inflammation (Hossfeld
et al., 2013), or suppressing SMC proliferation and preventing
restenosis (Che et al., 2016). Gene-eluting stents are also being
explored, as targeted gene therapy may upregulate production
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of growth factors or other molecules that may reduce intimal
hyperplasia and thrombosis [reviewed in detail in (Yin et al.,
2014) and (Adeel and Sharif, 2016)].
As a wider range of stent materials and therapeutics become
available with different dosage kinetics, stent selection may be
tailored to an individual patient’s needs, in order to deliver the
most beneficial dosage of a specific therapeutic(s) to the diseased
location for a precise duration.
NANOPARTICLE-MEDIATED DRUG
DELIVERY FOR RESTENOSIS
PREVENTION
For minor atherosclerotic lesions, targeted drug delivery via
nanoparticles may be a less invasive option than stents or vascular
grafts. Nanoparticles have been used clinically for targeted drug
delivery to cancerous tumors [reviewed in (Brannon-Peppas and
Blanchette, 2012)]. For atherosclerosis, many nanoparticles are
in clinical trials to aid in imaging and diagnosing lesions. These
specialized nanoparticles may be visible with imaging techniques
such as MRI, and others may deliver contrast agents directly to
the diseased site [reviewed in (Palekar et al., 2015)]. Here, we will
focus on nanoparticles that are in development for the delivery
of therapeutics to heal atherosclerotic lesions or prevent their
progression.
Nanoparticle Design
The success of any nanoparticle-mediated treatment is
determined by the nanoparticles’ ability to reach their target,
typically following intravenous injection, and to provide the
optimal dose of drug over a sustained period. These qualities are
determined by the nanoparticle size (Walkey et al., 2012; Tan
et al., 2013), surface properties (Walkey et al., 2012), particle
geometry (Tan et al., 2013), shear stress and flow rate in the
blood vessel (Klingberg et al., 2015), and drug release kinetics
(Panyam and Labhasetwar, 2004). Many different materials have
been used for fabricating drug-eluting nanoparticles, including
synthetic polymers [reviewed in (Wang et al., 2016)], lipoproteins
[reviewed in (Damiano et al., 2013; Harisa and Alanazi, 2014)],
lipids (Shiozaki et al., 2016), and metals (Weakley et al., 2011).
Different materials and design criteria may be needed depending
on the type of drug to be released, and the intended target of the
nanoparticle.
In addition to material considerations, the nanoparticle
targeting mechanism must be considered (Figure 3). After
injection, nanoparticles face several barriers to reaching their
target. They may be uptaken by macrophages, distribution
may be limited by blood flow, pressure gradients, or cellular
internalization [reviewed in (Blanco et al., 2015)]. Thus,
developing an effective targeting mechanism may increase
nanoparticles’ ability to reach their intended target. Direct
application via balloon angioplasty can be used, although
intravenous injection is more common. Nanoparticles may
naturally accumulate in atherosclerotic lesions, due to increased
endothelial permeability at the diseased site, a process known as
passive targeting (Duivenvoorden et al., 2014). This is the most
common approach for nanoparticles targeting atherosclerotic
lesions. Measuring the exact percent targeting efficiency of
nanoparticles in vivo is challenging, as nanoparticles rapidly
distribute throughout the body. Still, it is often possible to use
labeled nanoparticles to measure relative concentration in select
organs. For example, van der Valk et al. (2015) reported that
75% of plaque macrophages contained nanoparticles after IV
injection with passive targeting. Still, it is unknown what fraction
of injected nanoparticles remain in the body. Some materials
can alternatively be taken up by macrophages or monocytes in
the bloodstream, which may then accumulate in atherosclerotic
plaque (Katsuki et al., 2014). Others may be magnetically guided
to the diseased site (Chorny et al., 2009). Alternatively, active
FIGURE 3 | Mechanisms of nanoparticle delivery. Nanoparticles can be delivered directly to the lesion site by balloon angioplasty (A), they can be targeted using
conjugated antibodies that target specific surface markers on the lesion (B), or they can passively diffuse into the lesion due to increased endothelial permeability (C).
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targeting may be used, where nanoparticles are conjugated with
antibodies targeting specific proteins that are overexpressed at
sites of vascular injury, such as collagen IV (Fredman et al., 2015),
E-selectin (Ma et al., 2016), vascular cell adhesion molecule 1
(VCAM-1) (Nahrendorf et al., 2006), CD36 (Nie et al., 2015),
and αvβ3 integrin (Winter et al., 2008). These active targeting
systems may improve nanoparticles ability to reach their target.
For example, the collagen IV targeting system described in
Fredman et al. (2015) compared nanoparticle accumulation in
the liver, spleen, and aorta, and found that 70% of measured
particles were in the aorta. In addition, nanoparticles activated by
elevated shear stresses have been developed. Regions of luminal
narrowing caused by atherosclerosis, restenosis, or thrombosis
experience elevated levels of shear. Thus, nanoparticles that
release therapeutics when exposed to high shear stresses may
be effective for targeting atherosclerotic lesions or intimal
hyperplasia (Korin et al., 2012). Nanoparticle design is further
reviewed in Blanco et al. (2015).
Therapeutics for Nanoparticle-Mediated
Delivery
Since atherosclerosis is a very complex disease, combinations
of drugs or growth factors may be required for effective
treatment. Therapeutics targeting inflammatory cells, SMC
proliferation, thrombosis, and dysfunctional endothelial cells
have all shown promise in pre-clinical or clinical studies. HMG
Co-A reductase inhibitors (known as statins) are widely used for
systemic prevention of atherosclerosis, due to their pleiotropic
effects on cholesterol levels, SMC proliferation, inhibition of
inflammation, and promotion of endothelial health (Liao, 2005).
Statins have also been shown to stabilize and reverse advanced
atherosclerotic plaques in animals, but only at high doses
that are not approved for humans (Bea et al., 2002; Johnson
et al., 2005). Thus, the targeted delivery of higher doses via
nanoparticles may be able to reverse lesion progression without
the harmful effects of systemic delivery (Winter et al., 2008;
Zago et al., 2013; Duivenvoorden et al., 2014; Katsuki et al.,
2014; Alaarg et al., 2017). A recent study compared the effects
of simvastatin delivery via intravenously injected nanoparticles
fabricated from Polyethylene glycol (PEG)-ylated polymeric
micelles, high-density lipoproteins (HDL), and PEGylated
lysosomes on advanced atherosclerotic lesions, with the goal
of decreasing inflammation by reducing macrophage burden
(Alaarg et al., 2017). They found that PEGylated polymeric
micelles yielded greater reductions in macrophage burden in
advanced atherosclerotic plaques. This may be due to their slower
release of simvastatin and better ability to target macrophages
than the other nanoparticle types. This highlights the importance
of optimizing nanoparticle design and release kinetics for
maximum drug effectiveness.
Other molecules that target inflammation have also shown
promise in pre-clinical studies, including interleukin 10 (IL-10)
(Kamaly et al., 2016), steroids (Lobatto et al., 2015), and the
proresolving peptide Ac2-26, a protein that mimics the effects of
annexin 1 (Fredman et al., 2015). van der Valk et al. (2015) tested
IV injected, passive targeting, prednisolone-loaded liposomal
nanoparticles in a clinical study. While the nanoparticles had
shown promise in previous rabbit models (Lobatto et al.,
2015), they did not reduce inflammation in human lesions
(van der Valk et al., 2015). This may be due to the short-term
(10 days) nature of the study. The authors were also unable
to verify that the nanoparticles were accumulating in lesions.
In the future, nanoparticles that can be imaged may enable
lesions to be both visualized and treated at the same time, and
alleviate uncertainty over whether they are reaching their target.
Additionally, the lack of observed benefit in clinical studies may
be due to differences in atherosclerotic plaque formation in
animals compared to humans. Rabbits, like many small animals,
will not form plaque without a high-cholesterol diet. This results
in much higher cholesterol levels than are typically seen in
humans, and lesions that are more fatty and inflammatory that
human atherosclerotic plaques (Cullen et al., 2003; Yanni, 2004).
Mice are also commonly used, but require genetic manipulation
in addition to diet changes to develop plaque lesions (Calara
et al., 2001). Because small animals have similarly sized cells to
humans but much smaller blood vessels, there are fewer cells
involved in vessel function and plaque formation, which may
affect disease progression. These animals also have considerable
genetic homogeneity compared to humans, making it challenging
to replicate the large patient-to-patient variability typically seen
in humans (Cullen et al., 2003).
Chemotherapeutic agents have been studied as potential
atherosclerosis treatments due to their potent anti-proliferative
effects. Intravenously injected lipid nanoparticles loaded with the
drug carmustine successfully decreased lesion area by reducing
SMC proliferation, secretion of inflammatory factors, and
macrophage burden in rabbits (Daminelli et al., 2016). Shiozaki
et al. (2016) recently published a pilot clinical study where
cholesterol-rich non-protein nano-emulsion (LDE) particles,
which resemble low-density lipoproteins, were loaded with
paclitaxel oleate. When delivered systemically via intravenous
injection, the nanoparticles were able to reduce total plaque in
patients, though the difference was not significant (Shiozaki et al.,
2016).
Due of the complexity of atherosclerosis, the release
of multiple factors with different targets may provide a
greater benefit than one factor alone. Zhu et al. (2017)
designed bilayered poly(lactide-co-glycolide)/poly(vinyl alcohol)
(PLGA/PVA) nanoparticles loaded with VEGF-encoding plasmid
DNA and paclitaxel. Plasmid DNA encoding genes for growth
factors and other proteins can enable upregulated production
of a particular molecule without additional stimuli. This system
is designed to first increase VEGF production and heal the
endothelial layer, and then inhibit SMC proliferation. Results
were promising in a rabbit model, where histological analysis
showed endothelialization and decreased stenosis after 28 days
in animals treated with the bilayered nanoparticles, delivered via
angioplasty balloon (Zhu et al., 2017). Using plasmids to induce
growth factor production in cells may also help address concerns
over growth factor stability and reduce the risk of potentially
toxic growth factor burst releases. SiRNA and microRNA are also
potential therapeutics for treating atherosclerosis. Ma et al. (2016)
utilized intravenously injected polymer nanoparticles to deliver
microRNA to enhance endothelial function and reduce lesion
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size in a mouse model. Others have tested nanoparticle-mediated
siRNA delivery, with some success (Li et al., 2010; Leuschner
et al., 2011). For example, Leuschner et al. (2011) used siRNA to
prevent macrophage accumulation in atherosclerotic plaques.
Overall, nanoparticles have great potential for targeted
delivery of therapeutics to atherosclerotic lesions. A wide
range of materials, therapeutics, and molecular targets have
been investigated, although very few have advanced to clinical
trials. Therapeutics and nanoparticle properties discussed in
this section are summarized in Tables 2 and 3. With such a
complex disease, it is likely that multi-bioactive factor approaches
will be needed to effectively heal atherosclerotic lesions, as
single bioactive factor approaches may be ineffective. Moving
forward, issues such as consistency of nanoparticle fabrication,
optimization of nanoparticle targeting and bioactive molecule
release, premature nanoparticle clearance from the body, and the
potentially harmful effects of some nanoparticles must also be
addressed before these treatments become clinically available.
TARGETED BIOACTIVE MOLECULE
DELIVERY FOR ANEURYSM REPAIR
Bioactive Factor-Eluting Aneurysm Coils
One treatment method for saccular aneurysms is to “clip” or
tie off the aneurysm, to prevent blood from flowing into the
aneurysm to cause further dilation or bursting. Aneurysm coiling,
where a coil is inserted through the vasculature and into the
dilation, is often preferred over clipping because it is a much
less invasive procedure, and some aneurysms in the brain may
not be accessible for clipping. However, there is a risk that
over time blood may leak back into the dilation, causing a
secondary aneurysm. To address this, bioactive coils fabricated
from degradable polymers, such as PLGA, have been developed.
As bioactive polymers degrade, they trigger an inflammatory
response and tissue remodeling, which causes new tissue to fill
in and “heal” the aneurysm. This approach successfully reduced
the rate of residual aneurysms, although it did not improve the
TABLE 2 | Molecules delivered for aneurysm repair.
Molecule Delivery
mechanism
Effects
VEGF Aneurysm coil Enhance clot organization,
encourage endothelium
formation
FGF Aneurysm coil Promote wound healing
SEK-100 Aneurysm coil Accelerate healing
Tenascin-C Aneurysm coil Accelerate healing
SDF-1α Aneurysm coil Accelerate healing
Doxycycline Nanoparticles Prevent elastin degradation
TGF-β1 Nanoparticles Increase elastin synthesis
Hyaluronan oligomers Nanoparticles Increase elastin synthesis
Tissue plasminogen activator Nanoparticles Fibrinolysis of clots
Summary of molecules discussed in Section “Targeted Bioactive Molecule Delivery
for Aneurysm Repair,” their delivery mechanism, and effect on aneurysm repair.
overall rate of late aneurysm rupture or reintervention (Broeders
et al., 2016).
Bioactive factor-eluting coils may be able to further enhance
tissue healing. Growth factors such as VEGF may enhance
clot organization and encourage endothelium formation across
the aneurysm neck, preventing leakage into the coiled region
(Abrahams et al., 2001; Ohyama et al., 2004). Fibroblast growth
factor (FGF) is also well-established to promote wound healing
and new tissue formation. Coils coated with VEGF or FGF have
shown some success in animal studies (Abrahams et al., 2001;
Matsumoto et al., 2003; Ohyama et al., 2004; Tsumoto et al.,
2007). However, issues such as growth factor instability and
suboptimal release kinetics prevented these systems from moving
forward to clinical trials.
More recent approaches focus on developing more stable
growth factor delivery systems. Wang et al. (2014) tested
a coil coated with VEGF-loaded poly(D,L-lactide)-7co-(1,3-
trimethylene carbonate), and achieved a sustained VEGF release
curve over 25 days (Wang et al., 2014). However, it should
be noted that in vitro release experiments do not account for
the many complexities of the in vivo environment, including
proteases, the inflammatory response, and other factors that
may affect material degradation and molecule release rates.
Coils coated with more stable molecules such as SEK-1005, a
TGF-β inducing peptide known to promote wound healing,
have also been studied. While this system accelerated aneurysm
healing in rats, inconsistent growth factor loading was a
problem (Sano et al., 2010). Hamada et al. (2014) developed
a platinum coil with tenascin-C, a protein known to promote
fibrosis, loaded in a gellan sulfate core. Gellan sulfate is
a heparin-like molecule that strongly binds to tenascin-c,
resulting in a slow, controlled release. Additionally, because
the protein is released from the core, it avoids potentially
harmful buildup at the coil-arterial interface (Toma et al.,
2005; Miura et al., 2016). Pre-clinical trials showed improved
tissue formation over the aneurysm neck and improved intra-
aneurysmal clot organization, which may ultimately lead to
improved tissue remodeling (Hamada et al., 2014; Miura et al.,
2016). Recently, Gao et al. (2014) designed a coil with a
silk-fibroin coating that eluted stromal-cell derived factor 1α
(SDF-1α), which demonstrated a steady release of growth
factor over 21 days as the coating degraded. In preliminary
rat studies, they observed improved tissue growth within the
aneurysmal region compared to uncoated coils (Gao et al.,
2014).
While many different drugs and growth factors have potential
for healing aneurysms, designing coils with optimal release
kinetics, as with drug-eluting stents, is key. Delivering too much
of a molecule in a short period of time, or not delivering enough,
may have negative consequences. Thus, developing systems that
can provide controlled, sustained release of stable therapeutics for
enhancing clot organization and tissue growth is critical.
Nanoparticle Targeting for Aneurysm
Repair
Unlike molecules delivered on aneurysm coils, which aim
to “fill” existing saccular aneurysms with new tissue, MMP
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inhibitors may be effective at preventing elastin degradation
and halting aneurysm growth. Specifically, doxycycline has been
shown to reduce plasma MMP levels and inflammation of
the vessel wall (Baxter et al., 2002; Lindeman et al., 2009).
However, systemic delivery causes dose-dependent side effects
(Baxter et al., 2002). The Ramamurthi group has investigated
localized delivery of the MMP inhibitor doxycycline via PLGA
nanoparticles. Nanoparticles were functionalized with a cationic
amphiphile, which improved arterial uptake and enhanced MMP
inhibitory activity (Sivaraman and Ramamurthi, 2013). They also
tested nanoparticles loaded with smaller superparamagnetic iron
oxide nanoparticles, in addition to doxycycline, to magnetically
guide nanoparticles to the affected area (Sivaraman et al.,
2017). So far, results from the above studies have shown
promise in in vitro and ex vivo studies. Nosoudi et al. (2015)
fabricated poly(D,L-lactide) nanoparticles for the delivery of
the MMP inhibitor batimastat. Nanoparticles were conjugated
with an elastin antibody that binds to degrading elastin,
which may allow systemically delivered nanoparticles to target
locations of aneurysm. The approach has shown promise in
rats, where the intravenously injected nanoparticles were able
to prevent aneurysm expansion (Nosoudi et al., 2015). In
addition to MMP inhibitors, nanoparticle-mediated delivery of
hyaluronan-oligomers and of transforming growth factor β1
(TGF-β1) have also shown promise as therapeutics for increasing
elastin synthesis in vitro (Sylvester et al., 2013; Venkataraman
et al., 2016).
While the aforementioned systems are promising for targeting
aneurysms, bioactive molecule delivery to the vascular wall may
still be hindered by the presence of clots on the aneurysm
intraluminal surface. Combining these approaches with other
molecules such as tissue plasminogen activator, which allows for
controlled fibrinolysis of clots, may enhance their effectiveness.
Nanoparticle-mediated tissue plasminogen activator delivery has
shown promise in vitro for this purpose (Sivaraman et al., 2016).
Ultimately, a more comprehensive approach where nanoparticles
can first carefully dissolve clots in the aneurysm, and then deliver
MMP inhibitors to stabilize the aneurysm, may be necessary.
TARGETED DELIVERY IN VASCULAR
GRAFTS
Non-degradable Synthetic Vascular
Grafts
In severe cases of vascular disease, the affected area may need to
be replaced altogether with a bypass graft. Permanent synthetic
grafts have been widely used for replacing large diameter blood
vessels, in cases of both stenosis and aneurysm. They have
excellent mechanical strength and are relatively simple and cost
effective to produce on a large scale. However, in small diameter
(<6 mm diameter) vessels, synthetic grafts have an extremely
high risk of thrombosis and restenosis (Chard et al., 1987; Shah
et al., 2005; Hadinata et al., 2009). This may be due to incomplete
endothelialization, which is crucial for reducing the risk of
these complications (Allen et al., 1984). The surface properties
of commonly used synthetic materials can make these grafts
challenging to endothelialize (Moby et al., 2007). Incorporating
heparin or growth factors onto graft surfaces may help address
this challenge.
Heparinized Synthetic Grafts
Synthetic grafts with incorporated heparin have been tested as
early as the 1980s (Noishiki et al., 1986; Nojiri et al., 1987).
Exogenous heparin is well known to inhibit SMC proliferation,
prevent thrombosis, and encourage endothelialization, though
high systemic doses can be harmful (O’Donnell, 2012). Thus,
targeted delivery of heparin by immobilization on synthetic
grafts, particularly those fabricated from ePTFE or Dacron, has
been widely studied. Over the years, heparinized grafts have
been tested clinically for infrainguinal (Walluscheck et al., 2005),
femoropopliteal (Devine et al., 2001, Devine et al., 2004; Bosiers
et al., 2006; Daenens et al., 2009; Lindholt et al., 2011), and aortic
bypass grafting (Tsilimparis et al., 2015), and as arteriovenous
shunts (Shemesh et al., 2015). Overall, trials have been successful,
with patency rates comparable to native saphenous vein, and
improved over non-heparinized synthetic grafts. An example
illustrating this improvement is provided in Figure 4, which
shows the luminal surface of a GORE graft with and without
their CARMEDA BioActive Surface (CBAS R© heparin surface)
after 2 h of implantation in a canine carotid artery model (Biran
and Pond, 2017). The graft without the heparin coating has a
clear thrombotic occlusion, compared to the graft with the CBAS
heparin surface, which does not have any apparent thromboses.
In addition to its established effects, it may be possible that
heparin traps circulating growth factors, which may further
enhance endothelialization and improve patency rates.
Due to the success of these studies, some heparinized grafts,
such as the GORE PROPATEN graft, are now commercially
available for bypassing large diameter vessels and some smaller
diameter lower limb vessels. There have been mixed reports
concerning long term (5 years) patency rates compared to grafts
without heparin, which may be due to different immobilization
FIGURE 4 | Effect of heparin on synthetic graft thrombosis. A GORE ePTFE
vascular graft with or without a CBAS heparin surface coating, following a 2-h
implantation in a canine carotid model. Thrombosis is clearly visible in the graft
without the CBAS heparin surface. Figure reprinted from (Biran and Pond,
2017) with permission from W. L. Gore and Associates.
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methods (Devine et al., 2004; Samson et al., 2016). Covalent
immobilization techniques maintain heparin in its bioactive state
tethered to the graft, with limited release over time (Larm et al.,
1983). Other immobilization or coating methods may result in
faster heparin release, limiting its long-term protective effects.
Growth Factor Delivery
Growth factors have been tested to enhance endothelialization
of synthetic vascular grafts since the 1990s (Greisler et al., 1992;
Gosselin et al., 1996; Doi and Matsuda, 1997). They can either
be incorporated within coatings on the luminal surface of the
graft, or immobilized directly to the graft surface. Coatings are
more commonly used, as direct immobilization of growth factors
onto synthetic surfaces can be challenging, and additional surface
modifications may be required (Crombez et al., 2005). Fibrin
and fibronectin are the most widely used coatings to incorporate
growth factors, as these proteins alone directly bind to ECs, aiding
in their adhesion (Zilla et al., 1989; Meinhart et al., 2005; Dahl
et al., 2011; De Visscher et al., 2012).
Early studies incorporated FGF into fibrin glue coatings for
ePTFE grafts. This appeared to enhance endothelialization in
rabbits, though the potent effects of FGF on SMC proliferation
also increased neointimal growth (Greisler et al., 1992). Later,
growth factors more specific to ECs, such as VEGF, were
tested. VEGF is well-established to attract ECs and stimulate
EC proliferation (Ferrara and Devis-Smyth, 1997). When
incorporated into a Matrigel coating, VEGF resulted in enhanced
endothelialization, but also increased intimal hyperplasia in a rat
model (Randone et al., 2005). Similar increases in neointimal
growth were observed when VEGF was incorporated into
fibrin-coated grafts implanted in pigs (Walpoth et al., 2007). This
may be because VEGF can stimulate ECs to produce other growth
factors, including FGF, that increase SMC proliferation (Randone
et al., 2005). Thus, VEGF alone may not be an ideal growth factor
for this application.
Stromal-cell derived factor-1α has been used to stimulate
stem cell recruitment and accelerate healing. When implanted
in sheep, grafts with SDF-1α incorporated into a fibronectin
coating had less intimal growth compared to controls (De
Visscher et al., 2012). Other growth factors may be effective for
enhancing endothelialization and preventing intimal hyperplasia,
but have been largely studied on decellularized native arteries
rather than synthetic grafts, and are discussed in more detail
in Section “Decellularized Grafts for Growth Factor Delivery”
below. Overall, growth factor coatings have been less successful
than heparin immobilization. It is likely that combinations of
growth factors and other molecules will be needed to both
enhance endothelialization and prevent stenosis.
Other Molecules for Enhanced
Endothelialization
Antibodies specific to ECs may also be effective for enhancing
EC adhesion to synthetic surfaces. CD133 and VEGF receptor-2
are both specific to endothelial progenitor cells (EPCs). Lu et al.
(2013) incorporated CD133 antibodies into a collagen coating
layered with heparin, and observed enhanced endothelialization
in a porcine model (Lu et al., 2013). Grafts coated with
VEGF receptor-2 antibodies have also shown promise, leading
to increased adhesion of VEGF receptor-2-expressing cells in
in vitro studies (Liebler et al., 2016). Sapienza et al. (2009) coated
the luminal surface of grafts with antibodies against endogenous
FGF, PDGF, and TGF-β1. The growth factors bind to these
antibodies, which prevents them from activating local growth
factor receptors and stimulating SMC proliferation. This resulted
in less intimal hyperplasia in a 4 weeks pig study (Sapienza et al.,
2009), though longer term studies are needed to ensure that
the growth factor inhibition does not harm the endothelium.
Additional approaches for enhancing EC adhesion on synthetic
grafts are reviewed in (Melchiorri et al., 2013; Ren et al., 2015).
In addition to immobilization or incorporation within
coatings, some molecules can be incorporated within synthetic
grafts during fabrication. Ishii et al. (2008) incorporated
sirolimus and heparin into polycarbonate-siloxane polyurethane
during the fabrication process. These grafts showed increased
endothelialization and reduced intimal growth compared to
grafts with either drug alone in a rabbit model (Ishii et al., 2008).
The controlled release of heparin and other therapeutics has
made synthetic vascular grafts a viable alternative for several
bypass grafting applications. However, there have still not been
any reports of synthetic grafts with acceptable patency rates
for small diameter high-flow arteries such as the coronary
artery. Further optimization of therapeutic agents used and
their release kinetics may help address this need. However,
mechanical properties also play a critical role in graft success,
as compliance mismatch is well-established to trigger restenosis
(Abbott et al., 1987). Utilizing growth factor release to stimulate
endothelialization and tissue ingrowth, in addition to optimizing
graft compliance may lead to higher patency rates.
CONTROLLED RELEASE FROM TISSUE
ENGINEERED BLOOD VESSELS
Tissue engineered blood vessels can be fabricated in a variety
of ways. A common approach is to seed cells onto natural or
synthetic polymer scaffolds and allow the construct to mature and
remodel in a bioreactor (Niklason et al., 1999; Grassl et al., 2002).
Alternatively, TEBVs can be fabricated via cellular self-assembly
approaches, where constructs are fabricated entirely from cells
and their secreted extracellular matrix (L’Heureux et al., 1998;
Gwyther et al., 2011). While these approaches have had
some success, many challenges remain, such as establishing a
healthy, contractile SMC phenotype, optimizing graft strength
and compliance, and achieving complete endothelialization.
Localized and controlled bioactive factor delivery may be able to
address some of these problems.
The goal of many tissue engineering strategies is for native
tissue to ultimately replace the original synthetic or natural
polymer construct. To do this, the scaffold degradation rate
must be carefully engineered to match the rate of new tissue
growth. Thus, depending on the system, growth factors released
in TEBVs may be designed to mature the graft and enhance
cell proliferation, matrix deposition, or cell differentiation,
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compared to drug-eluting devices discussed earlier, which are
predominantly designed to prevent SMC proliferation and new
tissue growth. Therefore, it is important to consider how different
types of TEBVs will be integrated with host tissue when designing
controlled release systems.
Decellularized Grafts for Growth Factor
Delivery
Decellularized allogeneic vessels have had some clinical success
and are commercially available as alternatives to synthetic grafts
for small diameter vessels when autologous grafts are not
available (O’Banion et al., 2016). However, these grafts still
have low patency rates (56% primary patency at 1 year for
infrapopliteal bypass), primarily due to thrombosis (Randon
et al., 2010). As with synthetic vascular grafts, molecules such as
heparin may be used to enhance endothelialization and reduce
the risk of thrombosis and restenosis (Conklin et al., 2002;
Wang et al., 2007; Zhou et al., 2012; Dimitrievska et al., 2015).
Growth factors immobilized on graft surfaces have also been
studied (Conklin et al., 2004; Zeng et al., 2010; Zeng et al., 2012).
Specifically, grafts with immobilized brain-derived neurotrophic
factors (Zeng et al., 2012) and nerve growth factor (Zeng et al.,
2010) increased endothelial progenitor cell recruitment and
improved endothelialization and patency in rat models. While
growth factor coated decellularized allogeneic blood vessels are
a promising alternative as small-diameter bypass grafts, their
limited availability may ultimately prevent widespread use.
Degradable Electrospun Polymer
Scaffolds
Degradable polymer scaffolds can enable highly tuned release of
growth factors and other therapeutics. Polymers can be designed
and fabricated with customizable degradation rates, which play
a major role in release kinetics. Growth factor incorporation
in degradable polymeric TEBVs has been mainly limited to
electrospinning approaches. Other types of degradable TEBV
scaffolds may also be ideal for this application, but have been
largely unexplored. These are restricted to a small number
of studies where growth factors were tethered to degradable
polymer surfaces, rather than directly incorporated within the
scaffolds (Edlund et al., 2011; Melchiorri et al., 2015). In this
section, we will focus on molecules that are directly incorporated
within electrospun TEBVs during fabrication, rather than
tethered onto their surface.
Electrospinning is a process where an electric current is
applied to a polymer solution, which forms thin micro- or
nano-fibers that accumulate to create scaffold. Electrospun
scaffolds are advantageous because they have a porous structure
that provides a high surface area to volume ratio. This allows
for potential sustained delivery, as encased molecules must first
diffuse out of the polymer fiber, and then through the pores in the
graft. With electrospinning, parameters that may affect bioactive
molecule release, such as polymer composition, fiber diameter,
and pore size, can be easily tuned by adjusting manufacturing
parameters.
There are several methods for incorporating molecules within
electrospun fibers, reviewed in Rychter et al. (2017) and
summarized schematically in Figure 5. Direct blending is used
when the polymer and growth factor have similar solubility. The
polymer and therapeutic are combined prior to electrospinning
to form one solution, which is advantageous due to simplicity
in manufacturing. However, this may result in a high initial
burst release, as drugs and growth factors tend to be located
predominantly on the fiber surface (Kim et al., 2004). With
emulsion electrospinning, a typically aqueous solution of growth
factor is emulsified in a solution of polymer, which leads to
droplets of growth factor solution becoming encapsulated within
a polymer shell after electrospinning. Coaxial electrospinning
utilizes two different pumps to enable electrospinning of two
FIGURE 5 | Techniques for incorporating bioactive molecules within electrospun grafts. Molecules can be tethered to the material after electrospinning. With coaxial
electrospinning, the material and bioactive substance are combined during the electrospinning process, while being dispensed from two separate syringes.
Alternatively, with emulsion electrospinning or direct blending a solution of bioactive molecules is mixed with the material prior to electrospinning.
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different solutions together to create core-shell fibers, where
a growth factor solution core is contained in a polymer shell
(Rychter et al., 2017).
Electrospinning has been used to incorporate a wide range of
molecules into vascular grafts (summarized in Table 4). Many
of these designs have advanced to pre-clinical testing, including
grafts eluting VEGF to enhance endothelialization (Zhang et al.,
2013), heparin to prevent thrombosis (Huang et al., 2013; Yao
et al., 2014; Spadaccio et al., 2016), platelet-derived growth factor
(PDGF) to encourage SMC ingrowth (Zhang et al., 2013), SDF-1α
to recruit progenitor cells (Yu et al., 2012), paclitaxel to inhibit
restenosis (Innocente et al., 2009), and antibiotics to prevent
infection (Liu et al., 2015). Other molecules, such as steroids
(Chen et al., 2015) and anti-thrombotic drugs (Punnakitikashem
et al., 2014) have shown promise in in vitro studies for decreasing
inflammation and thrombosis, but have not progressed to in vivo
testing.
Grafts with incorporated heparin have shown promise
in canine studies. Wang et al. (2013) incorporated heparin
into poly(L-lactide-co-epsilon-caprolactone) electrospun
grafts by coaxial electrospinning. With the addition of a
pre-endothelialization step, they achieved an 89% patency rate
when heparin-eluting grafts were implanted in a canine femoral
artery for 24 weeks (Wang et al., 2013). However, grafts that
were not pre-endothelialized had very poor patency, even with
incorporated heparin (Wu et al., 2015).
As with other drug delivery applications, single therapeutic
approaches are often unsuccessful. Dual delivery approaches
may be more effective for addressing the multiple challenges
associated with implanting TEBVs. Zhang et al. (2013) developed
a two-layer electrospun vascular graft, with an inner VEGF-
loaded layer to induce endothelialization, and an outer PDGF-
loaded layer to stimulate SMC infiltration and new tissue growth.
Grafts remained patent for 4 weeks after implantation in rabbit
carotid arteries (Zhang et al., 2013). A similar system described
in Campagnolo et al. (2016) incorporated an osteopontin-derived
peptide in the luminal side to increase EC adhesion, and a
heparin-binding peptide on the abluminal side to trap secreted
VEGF and further enhance EC migration and proliferation.
In vitro tests showed promising increases in EC adhesion,
although this system has not yet been tested in vivo (Campagnolo
et al., 2016).
In the future, customizing the delivery of therapeutics for
individual patients may also help improve graft success, as
different patients may experience different rates of healing
and endothelialization. Wang et al. (2015) developed an
enzyme-functionalized vascular graft that locally produced nitric
oxide (NO) when a prodrug was administered systemically
in rats. After 30 days, explanted NO-producing grafts had
enhanced function, endothelialization, and reduced platelet
adhesion compared to grafts that did not produce NO (Wang
et al., 2015). This system may allow for the further tuning of
molecule delivery, as the molecule can locally be produced “on
demand” only when the patient needs it.
Overall, electrospinning is a well-suited graft fabrication
technique to incorporate a variety of different growth factors and
therapeutics into polymer scaffolds with highly tunable release
kinetics. However, while pre-clinical trials have been promising,
most still exhibit high stenosis rates that have prevented grafts
from moving forward to clinical trials. Optimizing delivery
of therapeutics may improve success. As with permanent
synthetic grafts, therapeutic delivery in combination with altering
other graft properties, such as compliance, may be critical
for improving overall patency. Additionally, parameters such
as pore size and fiber diameter may need to be optimized
to achieve adequate cellular infiltration and tissue ingrowth.
Electrospun grafts are reviewed in greater detail in Rychter et al.
(2017).
TABLE 4 | Molecules delivered in synthetic and tissue engineered vascular grafts.
Molecule Delivery mechanism Effects
Heparin Synthetic non-degradable grafts, degradable
TEBVs, decellularized allografts
Thrombosis prevention
FGF Synthetic non-degradable grafts Increase endothelialization
VEGF Synthetic non-degradable grafts, TEBVs Increase endothelialization
SDF-1α Synthetic non-degradable grafts, TEBVs Accelerate healing, recruit progenitor cells
PDGF antibody Synthetic non-degradable grafts Prevent SMC proliferation
TGF-β1 antibody Synthetic non-degradable grafts Prevent SMC proliferation
FGF antibody Synthetic non-degradable grafts Prevent SMC proliferation
CD133 antibody Synthetic non-degradable grafts Increase endothelialization
VEGF-receptor 2 antibody Synthetic non-degradable grafts Increase endothelialization
Brain-derived neurotrophic factors Decellularized allografts Increase endothelialization
Nerve growth factor Decellularized allografts Increase endothelialization
PDGF TEBVs Increase SMC ingrowth
Paclitaxel TEBVs Inhibit SMC proliferation and restenosis
Osteopontin-derived peptide TEBVs Increase EC adhesions
TGF-β1 TEBVs Increase SMC differentiation
Summary of molecules discussed in Sections “Targeted Delivery in Vascular Grafts” and “Controlled Release From Tissue Engineered Blood Vessels,” their delivery
mechanisms, and effects.
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Microsphere-Mediated Growth Factor
Delivery in Engineered Vascular Tissue
Microsphere (MS)-mediated growth factor delivery has been
used for years to mature and differentiate many engineered
tissues, including cartilage (Solorio et al., 2010), bone (Wang
et al., 2009), and stem cell aggregates (Carpenedo et al., 2009;
Solorio et al., 2010; Bratt-Leal et al., 2013). MS incorporation
alone can increase tissue strength (Solorio et al., 2012b; Dikina
et al., 2015), oxygen diffusion (Hayashi and Tabata, 2011; Tajima
and Tabata, 2013), cell viability (Garcia Cruz et al., 2013; Tajima
and Tabata, 2013), and uniformity of matrix deposition (Solorio
et al., 2012a). However, their application in vascular tissue
engineering has been limited. Others have incorporated gelatin
MS into cell spheroids, which were fused into vascular tissue,
but the MS primarily served to stabilize the construct and
were not used for growth factor delivery (Twal et al., 2014).
Our group has demonstrated that MS loaded with TGF-β1 can
be used to increase SMC contractile protein expression within
self-assembled SMC rings (Strobel et al., 2017). This approach
may be well-suited for applications where systemic or exogenous
delivery of a growth factors may be harmful or not possible, or for
thick, high cell density engineered tissues where growth factors
cannot diffuse through the entire construct.
Future of Growth Factor Delivery in
TEBVs
There is great potential for growth factors to be incorporated into
other systems, such as TEBVs fabricated from hydrogels or other
polymer scaffolds, which have yet to be explored. Incorporation
within scaffolds may help overcome diffusion limitations and
result in more uniform treatment than exogenous growth factor
delivery. It may also allow for continuous delivery of growth
factors after TEBV implantation, when exogenous or systemic
delivery is not feasible. Many different types of molecules
may be utilized, depending on the application. As discussed
above, cytokines for EC recruitment have proven essential for
preventing thrombosis and intimal hyperplasia. Other growth
factors such as PDGF and FGF may be able to stimulate new tissue
formation in degrading polymer grafts, and TGF-β1 may be used
to differentiate SMCs and drive TEBV maturation.
Tissue maturation may further be enhanced by adjustments to
growth factor release kinetics. Release of multiple growth factors
sequentially may be beneficial for vascular tissue engineering.
Gong and Niklason (2008) developed an optimized procedure
for fabricating TEBVs by treating them in vitro with exogenous
PDGF for 4 weeks to stimulate new tissue growth, and then
TGF-β1 for 4 weeks to promote differentiation. This sequential
delivery could also be obtained by designing biomaterials for
controlled dual-delivery, an approach that is already being used to
create microvasculatures within other engineered tissues (Chen
et al., 2007; Freeman and Cohen, 2009).
Delayed release of anti-inflammatory molecules days or
weeks after TEBV implantation is another potential application
of controlled release. While the inflammatory response may
be critical immediately following implantation, delayed release
of anti-inflammatory molecules may prevent problems such
as intimal hyperplasia from occurring later (Washington and
Bashur, 2017).
Spatiotemporal control of the release of multiple growth
factors may also be applied to modeling focal vascular diseases.
Because many vascular diseases such as atherosclerosis, intimal
hyperplasia, and aneurysm affect only one region of the vessel,
delivering growth factors or other molecules specifically within
a focal region within TEBVs may enable the creation of such
models. This could potentially be accomplished with modular
TEBV approaches and controlled release systems (Strobel et al.,
2018). Spatially controlled release may also be advantageous
for culturing and maintaining distinct tissue phenotypes in
multi-tissue constructs such as trachea, which have alternating
smooth muscle and cartilage regions (Dikina et al., 2018).
REGULATORY CHALLENGES
There are many challenges when designing an effective
drug-eluting medical device or tissue engineered construct.
In addition to design challenges, regulatory approval of these
products is a major consideration. Medical devices, drugs, and
biologics are all regulated by the Food and Drug Administration
in the United States, to ensure safety and efficacy of any
new product. Drug-eluting stents pose a regulatory challenge
because they contain both a device and a drug, making them
a combination product. However, they have now been in use
for many years, and regulatory guidelines are well-established
[described in detail in Food and Drug Administration [FDA]
(2008)]. Because there are many approved drug-eluting stent
designs, and they often utilize already approved drugs, new
designs may have a more clear pathway to approval, although
extensive in vitro, pre-clinical, and clinical studies are still
required. However, experimental designs and therapeutics, such
as siRNA eluting stents, may be considered new drugs and require
even more thorough safety and efficacy testing.
The wide range of nanoparticle designs can make them
more challenging to regulate. For example, size may play
a critical role in the safety of some nanoparticle-based
therapeutics, but have no effect on the safety of others, depending
on the material and delivery and targeting mechanisms.
Nanoparticles are usually regulated under the same standards
as other drugs. However, because there may be additional
concerns about toxicity, clearance, and biodistribution, some
additional recommendations are in place [detailed in Food
and Drug Administration [FDA] (2017)]. The largest barrier
to approval is the often limited understanding of nanoparticle
pharmacokinetics. Improvements in pharmacokinetic modeling
may help accelerate the approval of these therapies in the future.
Regulation of nanoparticles is reviewed in detail in Narang et al.
(2013).
Tissue engineered blood vessels provide a unique
regulatory challenge, because they are a relatively new
technology that combines the regulatory umbrellas of
biologics, tissues, and devices. While ASTM and ISO
standards exist for testing synthetic vascular grafts
(American National Standard [ANS], 2010) and some other
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tissue engineered products, none specifically cover the
characterization and manufacturing of TEBVs (Lee et al., 2010).
With TEBVs, additional factors need to be considered such
as how cells will affect scaffold properties over time. Because
cells, materials, scaffolds, and eluted molecules are produced
separately, quality control testing may need to be performed both
before and after TEBV fabrication. Deciding at which timepoints
during TEBV maturation and remodeling that they should be
tested can also be a challenge (Lee et al., 2010). As more TEBVs
move forward into clinical trials, more regulatory guidelines will
be established to help address these challenges.
SUMMARY AND UNMET CHALLENGES
Localized bioactive molecule delivery has enormous potential
for more effective and safe treatment of cardiovascular diseases
than systemic treatments. Drug-eluting stents are already widely
used clinically and have shown great success. Other systems, such
as bioactive molecule-eluting nanoparticles and aneurysm coils,
still have some challenges to overcome before they can be used
clinically. While these fields have made tremendous progress,
there is only a limited ability to predict how effective new designs
will be in vivo. While computational modeling has improved
our ability to predict release curves, these models are still
highly limited. Patient-to-patient variability in the inflammatory
and immune responses, thrombus formation, healing, and
re-endothelialization makes this an exceptionally challenging
problem, as these factors can affect material degradation,
molecule release, and diffusion into the tissue. In the future, more
advanced models may further improve our ability to streamline
drug-eluting medical device design and maximize the patient
benefit of these products. Existing drug-release models are often
based on animal studies, which may not translate to humans. It
is possible that TEBVs may in the future be used to better mimic
the human in vivo environment in vitro, to create a more realistic
system for modeling drug release profiles. TEBVs may also allow
for the fabrication of patient-specific disease models, which may
further improve our ability to account for patient-to-patient
variability.
Combining nanoparticle and drug-eluting stent approaches
may in the future allow for sequential delivery of multiple factors,
allowing for more comprehensive, customized treatments. The
enormous number of nanoparticle systems and drug-eluting
stents in development may ultimately provide physicians with
a wide range of options, enabling them to customize targeted
drug delivery for each individual patient’s needs. Future work
in the field may focus on combining several technologies to
deliver multiple therapeutics sequentially, and to allow for such
customization.
Vascular bypass grafts have made significant progress as
alternatives to autologous grafting for large and medium blood
vessel bypass procedures, but progress has been slow for small
diameter applications. TEBVs for coronary artery bypass grafting
have achieved success in pre-clinical studies, but have yet to
be applied clinically. Some of the challenges currently facing
the field include optimization and in vivo measurement of
drug release kinetics, the need for multi-drug approaches with
differing release profiles, problematic compliance mismatch
between vascular grafts and native vessels, and insufficient tissue
ingrowth into vascular grafts and TEBVs. As with other vascular
interventions, future work in tissue engineering may focus on
optimizing biomaterials to release multiple growth factors or
other molecules, to fabricate and mature tissue into biomimetic
grafts.
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